The Bill & Melinda Gates Foundation sold almost all of its shares in biotechnology, health-care, and pharmaceutical companies in the quarter that ended June 30, according to a regulatory filing, reports The Wall Street Journal.

The foundation sold 2.5 million shares in Johnson & Johnson, 14.9 million shares in Schering-Plough Corp., almost 1 million shares in Eli Lilly & Co., 8.1 million shares in Merck & Co., and 3.7 million shares in Wyeth. It no longer has any shares in these companies.

There is anxiety among drug companies and health-care insurance firms about the Obama administration’s plans to overhaul health care.

Michael Larson, the manager of the Gates foundation’s investments, did not comment in the article.

(A paid subscription is required to view this article.)